Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: While BRCA1/2 genes are commonly investigated, variants of unknown significance (VUS) and variants with potential splice effect are still being detected and they represent a substantial challenge in genetic counseling and therapy. Materials and methods: Out of genetically tested 3,568 hereditary breast and ovarian cancer probands five, functionally not investigated variants with potential splice-modifying effect were subjected to functional characterization. Transcript-level analysis on peripheral blood-derived RNA of the carriers was performed to test aberrant splicing. The completeness of the aberrant splicing event was also studied, existence and extent of nonsense-mediated decay was even addressed. Clinical and phenotype data, pedigree and co-segregation analyses were also done. Locus-specific loss of heterozygosity (LOH) in tumor tissues was additionally tested. Results: In case of the BRCA1:c.4484+4dupA and the BRCA1:c.5407-10G>A variants functional results allowed us to reclassify them from VUS into likely pathogenic category. BRCA1:c.4358-31A>C, by producing incomplete aberrant splicing, was highlighted as strong VUS, but in lack of other supporting evidence, re-categorization was not possible. The likely pathogenic assertion of previously not reported BRCA2:c.8487G>T was reinforced based on its spliceogenic property and tumor LOH, while BRCA2:c.793G>A failed to present aberrant splicing in spite of suggestive predictions, which altered its original VUS evaluation into likely benign class. Conclusion: We presented molecular and clinical evidence for reclassification of four out of five BRCA1/2 variants. Both up- and down-classification harbour important clinical significance. Patients carrying re-classified pathogenic variants in the future will not be dropped out from medical surveillance, preventive measures, treatment and predictive family screening in relatives at risk.
Abstract
Purpose: While BRCA1/2 genes are commonly investigated, variants of unknown significance (VUS) and variants with potential splice effect are still being detected and they represent a substantial challenge in genetic counseling and therapy. Materials and methods: Out of genetically tested 3,568 hereditary breast and ovarian cancer probands five, functionally not investigated variants with potential splice-modifying effect were subjected to functional characterization. Transcript-level analysis on peripheral blood-derived RNA of the carriers was performed to test aberrant splicing. The completeness of the aberrant splicing event was also studied, existence and extent of nonsense-mediated decay was even addressed. Clinical and phenotype data, pedigree and co-segregation analyses were also done. Locus-specific loss of heterozygosity (LOH) in tumor tissues was additionally tested. Results: In case of the BRCA1:c.4484+4dupA and the BRCA1:c.5407-10G>A variants functional results allowed us to reclassify them from VUS into likely pathogenic category. BRCA1:c.4358-31A>C, by producing incomplete aberrant splicing, was highlighted as strong VUS, but in lack of other supporting evidence, re-categorization was not possible. The likely pathogenic assertion of previously not reported BRCA2:c.8487G>T was reinforced based on its spliceogenic property and tumor LOH, while BRCA2:c.793G>A failed to present aberrant splicing in spite of suggestive predictions, which altered its original VUS evaluation into likely benign class. Conclusion: We presented molecular and clinical evidence for reclassification of four out of five BRCA1/2 variants. Both up- and down-classification harbour important clinical significance. Patients carrying re-classified pathogenic variants in the future will not be dropped out from medical surveillance, preventive measures, treatment and predictive family screening in relatives at risk.
참고문헌 (31)
- Robson M, "Clinical practice. Management of an inhe-rited predisposition to breast cancer", N Engl J Med, 357, pp.154~162 (2007)
- Federici G, "Variants of uncertain significance in the era of high-throughput genome sequencing : a lesson from breast and ovary cancers", J Exp Clin Cancer Res, 39, pp.46~ (2020)
- Singer CF, "Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations", Eur J Cancer, 106, pp.54~60 (2019)
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Kuchenbaecker KB, "Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers", JAMA, 317, pp.2402~2416 (2017)
- Parsons MT, "Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants : an ENIGMA resource to support clinical variant classification", Hum Mutat, 40, pp.1557~1578 (2019)
- Harper K, "BRCA exchange launches", Cancer Discov, 9, pp.311~312 (2019)
- Murray ML, "Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance : variant reclassification and surgical decisions", Genet Med, 13, pp.998~1005 (2011)
- Bevers TB, "NCCN clinical practice guidelines in oncology : breast cancer screening and diagnosis", J Natl Compr Canc Netw, 7, pp.1060~1096 (2009)
- Deignan JL, "Points to consider in the reevaluation and reanalysis of genomic test results : a statement of the American College of Medical Genetics and Genomics(ACMG)", Genet Med, 21, pp.1267~1270 (2019)
- Orban TI, "Emerging roles of BRCA1 alternative splicing", Mol Pathol, 56, pp.191~197 (2003)
- Stoilov P, "Defects in pre-mRNA processing as causes of and predisposition to diseases", DNA Cell Biol, 21, pp.803~818 (2002)
- Marmolejo DH, "Overview of here-ditary breast and ovarian cancer(HBOC)guidelines across Europe", Eur J Med Genet, 64, pp.104350~ (2021)
- Culp M, "ada : an R package for stochastic boosting", J Stat Softw, 17, pp.1~27 (2006)
- Breiman L, "Random forests", Mach Learn, 45, pp.5~32 (2001)
- Liu X, "dbNSFP v4 : a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs", Genome Med, 12, pp.103~ (2020)
- Nazari I, "Branch point selection in RNA splicing using deep learning", IEEE Access, 7, pp.1800~1807 (2019)
- Paggi JM, "A sequence-based, deep learning model accurately predicts RNA splicing branchpoints", RNA, 24, pp.1647~1658 (2018)
- Papp J, "High prevalence of germline STK11 mutations in Hungarian Peutz-Jeghers Syndrome patients", BMC Med Genet, 11, pp.169~ (2010)
- Kopanos C, "VarSome : the human genomic variant search engine", Bioinformatics, 35, pp.1978~1980 (2019)
- Goldgar DE, "Integrated evaluation of DNA sequence variants of unknown clinical significance : application to BRCA1 and BRCA2", Am J Hum Genet, 75, pp.535~544 (2004)
- Wimmer K, "AG-exclusion zone revisited : lessons to learn from 91 intronic NF1 3’ splice site mutations outside the canonical AG-dinucleotides", Hum Mutat, 41, pp.1145~1156 (2020)
- Findlay GM, "Accurate classification of BRCA1 variants with saturation genome editing", Nature, 562, pp.217~222 (2018)
- Houdayer C, "Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico", in vitro studies on BRCA1 and BRCA2 variants, 2012, pp.33, 1228~1238
- Chehade R, "Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific", Breast Cancer Res, 18, pp.87~ (2016)
- highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms, "Hum Mol Genet", 2016, 2256~2268
- Zhang L, "cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation", Mutat Res, 663, pp.84~89 (2009)
- Walsh MF, "Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes", Hum Mutat, 39, pp.1542~1552 (2018)
- Maxwell KN, "BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers", Nat Commun, 8, pp.319~ (2017)
- Bonnet C, "Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene", J Med Genet, 45, pp.438~446 (2008)
- Mesman RL, "Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2", Genet Med, 22, pp.1355~1365 (2020)